NanoViricides to Begin Phase II Monkeypox Treatment Trial Soon
NanoViricides announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to begin soon in the Democratic Republic of Congo. Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research Pvt. Ltd., and associates in DRC. The CRO personnel are expected to visit the Site for final preparations and for staff training in the first week of April, 2026. Enrollment and dosing of patients is expected to begin after the staff training is completed. The Company previously reported that it has received approval to start said Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo. The Phase II clinical trial will evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection. MPox Clade I is endemic in DRC and all cases in the clinical trial are expected to be of the Clade I virus. The other prominent MPox virus, MPox Clade II is substantially less severe an infection than MPox Clade I.
Trade with 70% Backtested Accuracy
Analyst Views on NNVC
About NNVC
About the author
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
- Zentalis Pharmaceuticals Surge: Zentalis Pharmaceuticals' stock rose 17.65% to $4.40 in after-hours trading, with no new news but bolstered by a corporate update on January 6, 2026, highlighting key milestones in its azenosertib development program, which has renewed investor confidence in its pipeline progress.
- LifeMD Secures Financing: LifeMD's stock climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability, with $30 million committed, which is expected to support the company's organic growth initiatives.
- NanoViricides Attracts Speculative Interest: NanoViricides' stock advanced 11.11% to $1.24, drawing speculative interest in after-hours trading despite no new announcements, indicating ongoing market enthusiasm for biotech companies.
- Neurogene Participates in Healthcare Conference: Neurogene's stock increased 2.06% to $18.29 as the management team prepares to present at the 44th Annual J.P. Morgan Healthcare Conference, enhancing market expectations for its future developments.
NanoViricides: Fiscal Q3 Earnings Snapshot
Company Financial Performance: NanoViricides Inc. reported a loss of $2.2 million in its fiscal third quarter, equating to a loss of 14 cents per share.
Location and Reporting Source: The company is based in Shelton, Connecticut, and the information was generated by Automated Insights using data from Zacks Investment Research.
Biotech Alert: Searches spiking for these stocks today
Surge in Biotech Stock Interest: Several biotech companies, including NanoViricides and Tenaya Therapeutics, are experiencing significant increases in search activity, indicating heightened investor interest in their innovative therapies and clinical developments.
Key Developments in Clinical Trials: Companies like GeoVax Labs and Tonix Pharmaceuticals are advancing their clinical programs, with promising results in vaccine development and pain management therapies, while others like Editas Medicine and TC Biopharm are making strategic moves to enhance their market positions.
Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more (NASDAQ:NVDA)
Upcoming Earnings Reports: Several high-profile companies, including NVIDIA, Salesforce, and Lululemon, are set to report their quarterly earnings next week, with analysts closely monitoring their performance for insights into the tech and retail sectors.
Analyst Sentiment: While some companies like NVIDIA and Salesforce have positive outlooks from analysts, others like Nordstrom and Lululemon face mixed reviews due to operational challenges and market conditions, impacting their stock ratings.
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
Clinical Development Update: NanoViricides, Inc. is advancing its broad-spectrum antiviral drug NV-387, which has shown superior efficacy in animal trials against major respiratory viruses like Influenza, COVID-19, and RSV, with plans for Phase II clinical trials to evaluate its effectiveness in humans.
Market Potential and Future Plans: The company aims to expand NV-387's application to a wider range of viruses, anticipating significant market growth in antiviral treatments, while also seeking collaborations with larger pharmaceutical companies to expedite development and commercialization efforts.
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Increasing Demand for Antiviral Drugs: The global demand for antiviral drugs is rising due to the prevalence of viral diseases, with a projected market revenue of $51.18 billion in 2024, driven by innovations in treatments like NanoViricides' NV-387, which shows broad-spectrum efficacy against multiple viruses.
Biotech Developments and Collaborations: Companies such as BioCryst Pharmaceuticals and Veru Inc. are advancing their antiviral therapies, while NanoViricides seeks collaborations to expedite regulatory approvals for its promising drug NV-387, aimed at addressing gaps in COVID-19 treatment options.
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
- Zentalis Pharmaceuticals Surge: Zentalis Pharmaceuticals' stock rose 17.65% to $4.40 in after-hours trading, with no new news but bolstered by a corporate update on January 6, 2026, highlighting key milestones in its azenosertib development program, which has renewed investor confidence in its pipeline progress.
- LifeMD Secures Financing: LifeMD's stock climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability, with $30 million committed, which is expected to support the company's organic growth initiatives.
- NanoViricides Attracts Speculative Interest: NanoViricides' stock advanced 11.11% to $1.24, drawing speculative interest in after-hours trading despite no new announcements, indicating ongoing market enthusiasm for biotech companies.
- Neurogene Participates in Healthcare Conference: Neurogene's stock increased 2.06% to $18.29 as the management team prepares to present at the 44th Annual J.P. Morgan Healthcare Conference, enhancing market expectations for its future developments.
NanoViricides: Fiscal Q3 Earnings Snapshot
Company Financial Performance: NanoViricides Inc. reported a loss of $2.2 million in its fiscal third quarter, equating to a loss of 14 cents per share.
Location and Reporting Source: The company is based in Shelton, Connecticut, and the information was generated by Automated Insights using data from Zacks Investment Research.
Biotech Alert: Searches spiking for these stocks today
Surge in Biotech Stock Interest: Several biotech companies, including NanoViricides and Tenaya Therapeutics, are experiencing significant increases in search activity, indicating heightened investor interest in their innovative therapies and clinical developments.
Key Developments in Clinical Trials: Companies like GeoVax Labs and Tonix Pharmaceuticals are advancing their clinical programs, with promising results in vaccine development and pain management therapies, while others like Editas Medicine and TC Biopharm are making strategic moves to enhance their market positions.
Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more (NASDAQ:NVDA)
Upcoming Earnings Reports: Several high-profile companies, including NVIDIA, Salesforce, and Lululemon, are set to report their quarterly earnings next week, with analysts closely monitoring their performance for insights into the tech and retail sectors.
Analyst Sentiment: While some companies like NVIDIA and Salesforce have positive outlooks from analysts, others like Nordstrom and Lululemon face mixed reviews due to operational challenges and market conditions, impacting their stock ratings.
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
Clinical Development Update: NanoViricides, Inc. is advancing its broad-spectrum antiviral drug NV-387, which has shown superior efficacy in animal trials against major respiratory viruses like Influenza, COVID-19, and RSV, with plans for Phase II clinical trials to evaluate its effectiveness in humans.
Market Potential and Future Plans: The company aims to expand NV-387's application to a wider range of viruses, anticipating significant market growth in antiviral treatments, while also seeking collaborations with larger pharmaceutical companies to expedite development and commercialization efforts.
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Increasing Demand for Antiviral Drugs: The global demand for antiviral drugs is rising due to the prevalence of viral diseases, with a projected market revenue of $51.18 billion in 2024, driven by innovations in treatments like NanoViricides' NV-387, which shows broad-spectrum efficacy against multiple viruses.
Biotech Developments and Collaborations: Companies such as BioCryst Pharmaceuticals and Veru Inc. are advancing their antiviral therapies, while NanoViricides seeks collaborations to expedite regulatory approvals for its promising drug NV-387, aimed at addressing gaps in COVID-19 treatment options.
